Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce
Date:7/6/2009

DETROIT, July 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD), announced today that it is in the process of instituting an indefinite reduction in its workforce of approximately 350 employees in order to align its expenses with the current voluntary cessation of its manufacturing operations in connection with the recent action by the United States Food and Drug Administration (the "FDA"). The timing of the resumption of manufacturing operations, in whole or in part, depends on the outcome of discussions with the FDA. This should have no effect on distributed product sales that we market in the US. The Company may recall some employees to assist us in any remedial action plan that is developed based on such discussions.

Additionally, the Company announced that it has been informed by JPMorgan Chase Bank, N.A. that its $10 million line of credit, of which there is a zero balance, is not available to be drawn down upon until the FDA matter is resolved. This does not have any material impact on the Company's current financial position.

Manufactured product sales have represented approximately one-third of the Company's net sales revenue. For Fiscal 2009, net sales of manufactured products and of distributed products were $111.8 million and $225.4 million, respectively. We anticipate working with the FDA for resolution as expeditiously and effectively as possible. We fully expect to emerge as a stronger company while providing quality products to our customers.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
4. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets
5. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009
8. Caraco Pharmaceutical Laboratories, Ltd. to Announce Third Quarter of Fiscal Year 2009 Results on January 29, 2009
9. Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter
10. Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter
11. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics, who is celebrating their 25th ... humble beginnings to being an internationally recognized leader in their industry. , "We are ... Charlie Lawrence, President of Workrite. “Workrite recognized the importance of good ergonomics before ...
(Date:2/10/2016)... ... February 09, 2016 , ... Western University ... free oral screenings to 150 children in kindergarten through third grade at Hurley ... Dental Medicine joined Chinese American Dental Society of Southern California volunteers for Give ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... It’s that ... Traci Davis, the new president of the Interscholastic Athletic Association of Maryland (IAAM), Hall ... well how quickly fitness goals are cast aside. , That’s why one of her ...
(Date:2/9/2016)... ... , ... February is Heart Awareness Month, and to celebrate Health Quest Chiropractic ... the American Heart Association, New Mexico chapter. , A Heart Rate Variability (HRV) scan ... INSiGHT Pulse Wave Profiler utilizes a non-invasive technology to determine a heart’s ability to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 On Tuesday, February 9th, the ... with its Arthritis Advisory Committee to discuss ... & Johnson,s Remicade and most likely the ... U.S. The Biologics Prescribers Collaborative (BPC) along ... for Patient Access, American Association of Clinical ...
(Date:2/10/2016)... aims to ensure 2,50,532 children between the ages ... th birthday   --> The campaign ... - 5 years reach the milestone of their 5 ... aims to ensure 2,50,532 children between the ages of 2 ... birthday   India , have launched the "Joy of Five" ...
(Date:2/9/2016)... -- Misonix, Inc. (NASDAQ: MSON ), an international ... innovative therapeutic ultrasonic products for spine surgery, skull-based ... and other surgical applications, today announced financial results ... of fiscal year 2016 ended December 31, 2015. ... Highlights for the second quarter and first ...
Breaking Medicine Technology: